Vergent Bioscience has a world-class management team with a track record of successfully developing groundbreaking medical technologies that transform patient care.
John Santini, PhD
President & Chief Executive Officer
Dr. Santini is a life science executive, serial entrepreneur, inventor, and scientist who has focused on the creation and growth of businesses developing next-generation pharmaceuticals, drug delivery systems, biosensors, and surgical oncology products for more than 20 years. He currently serves as the President and CEO of Vergent Bioscience.
During his career, Dr. Santini has negotiated and executed collaborations and license agreements with major pharmaceutical and medical device companies and has raised over $100M in venture capital and corporate funding for his companies. Dr. Santini was the first industry scientist to be honored as one of Popular Science Magazine’s “Brilliant Ten,” and he was named one of the Top 100 “Young Innovators” in the world by Technology Review Magazine. He has published work in top scientific journals such as Nature, Nature Biotechnology, and Science Translational Medicine, has over 80 issued US and international patents, and his work has garnered a Technology Pioneer award from the World Economic Forum (Davos, Switzerland) and a Gold Medal from the Edison Awards in the Science and Medical, Game Changers category. Dr. Santini earned a PhD in chemical engineering from MIT in the laboratories of Professors Robert Langer and Michael Cima as a National Science Foundation Fellow, and a bachelor’s degree in chemical engineering from the University of Michigan.
Eric Bensen, PhD
Vice President, Research and Development
Dr. Eric Bensen is Vice President of Research & Development at Vergent Bioscience, where he leads the clinical and scientific teams driving Vergent’s intraoperative imaging agent programs. Prior to his tenure at Vergent, Dr. Bensen served as Vice President of In Vitro Laboratory Services at MD Biosciences, where he was responsible for establishing and leading an in vitro services laboratory specializing in inflammatory disease models. In both academic and industry settings, he has successfully implemented study programs, developed new methods for analyzing complex biological systems and secured grants and external funding.
Dr. Bensen has a bachelor’s degree in biochemistry from UC Riverside and a PhD in biological chemistry from UCLA, where he studied cellular protein trafficking. As a postdoctoral fellow at the University of Minnesota, he conducted research on the cell cycle regulation of pathogenic yeast.
Curtis Scribner, MD
Chief Medical Officer
Dr. Scribner is a board-certified internal medicine specialist with broad experience in drug development, having served as a clinical investigator, regulatory reviewer, and strategic product life-cycle consultant. He has spent 10 years at the US FDA’s Center for Biologics Evaluation and Research (CBER) reviewing all phases of clinical development for multiple therapeutic approaches (blood, plasma, recombinant proteins, cells, tissues, vaccines, etc.).
In addition to his work at the FDA, Dr. Scribner served as the Chief Regulatory Officer at BioMedicines/Intarcia, a venture-based drug, biologic and combination development company. He also brings to Vergent more than 25 years of experience as a consultant to drug and biologics companies working on discovery and preclinical models through clinical trials, data and safety monitoring, and strategic and operational regulatory interactions in the US and Europe. He has extensive experience designing and executing GCP-quality clinical studies, and has helped develop multiple orphan drug, rare pediatric disease, breakthrough, fast track, and regenerative medicine advanced therapy (RMAT) designation requests. Dr. Scribner’s areas of expertise include medical imaging, oncology, immunology, very rare and orphan diseases, and cell and gene therapy. He earned his MD from the University of Colorado School of Medicine, and an MBA from the University of Maryland
Board of Directors
Our board of directors and advisors include world-class surgeons, scientists, and biotech executives committed to revisualizing cancer surgery
Co-founder, Board Member
Tyson Foods, Google X, Highland Capital Partners, OrthoHelix, Tornier, J&J, Harvard
Ryan Egeland, MD, PhD
Crossfire Medical, Cardiovascular Systems Inc, Medtronic, Harvard, Oxford (Rhodes Scholar)
Responsive Orthopedics, spineTECH, Tornier, American Medical Systems
Co-founder, Board Member
Chamilia, Morgan Stanley and Salomon SmithBarney/Citigroup, West Point
Spring Mountain Capital, Merrill Lynch, Harvard
Margo Shoup, MD, MBA,
Orlando Health Cancer Institute, Nuvance Health, Northwestern, Memorial Sloan-Kettering
John Santini, PhD
Vergent Bioscience, ApoGen Biotechnologies, MicroCHIPS Biotech, MIT